Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Replagal alternative dose and regimen pharmacokinetic/pharmacodynamic study in Fabry disease
2004-000772-14Phase 2Completed
- Sponsor
- Transkaryotic Therapies
- Start
- Jun 2004
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of agalsidase alfa in Fabry disease (FD) (3 arms), sponsored by Transkaryotic Therapies. Primary endpoint: Plasma globotriaosylceramide. Started Jun 2004; status: completed.
02
Drugs
agalsidase alfa
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2004-000772-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000772-14.